| Literature DB >> 25098238 |
D Gardner1, L E Jeffery, D M Sansom.
Abstract
T cell activation is a key event in the adaptive immune system and vital in the generation of protective cellular and humoral immunity. Activation is required to generate CD4 effector T cell responses and provide help for B cell and cytotoxic T cell responses. While defective T responses to foreign antigen result in infectious pathology, over-reactive T cell responses against self-antigens result in autoimmunity and, in a transplantation setting, tissue rejection. Understanding how T cell activation is normally regulated is critical to therapeutic intervention and the CD28/CTLA-4 (CD152) pathway represents the initial activation checkpoint in molecular terms. In particular, while the CTLA-4 pathway is well established as an essential regulator of self-reactivity, its mechanism of action is still uncertain. Such mechanistic issues are important given its central position in T cell activation and the increasing number of therapeutic modalities aimed at manipulating the CD28/CTLA-4 pathway. Here, we provide an updated view of CTLA-4 biology, reviewing the established features of the system and highlighting its interplay with CD28. We then discuss how recent progress in our understanding of this pathway affects our interpretations following intervention. © Copyright 2014 The American Society of Transplantation and the American Society of Transplant Surgeons.Entities:
Keywords: Basic (laboratory) research/science; costimulation; fusion proteins and monoclonal antibodies: belatacept; fusion proteins and monoclonal antibodies: costimulation molecule specific; immunosuppressant; immunosuppression/immune modulation; translational research/science
Mesh:
Substances:
Year: 2014 PMID: 25098238 DOI: 10.1111/ajt.12834
Source DB: PubMed Journal: Am J Transplant ISSN: 1600-6135 Impact factor: 8.086